Stock IMM IMMUPHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Highlights ImmuPharma plc

Equities

IMM

GB0033711010

Delayed London S.E.
Other stock markets
 13:42:57 17/05/2024 BST 		5-day change 1st Jan Change
2.3 GBX +2.22% Intraday chart for ImmuPharma plc +6.24% +37.97%
04-29 Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director CI
04-02 Immupharma jumps amid new IP strategy for P140 technology platform AN

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immupharma jumps amid new IP strategy for P140 technology platform
AN
ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform
CI
Incanthera says first order from skincare deal doubles
AN
Stocks make tepid start to new week
AN
AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss
AN
EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up
AN
EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows
AN
ImmuPharma Appoints Contract Research Organization for Late-stage Lupuzor Trial
MT
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm
CI
Incanthera signs skincare stocking deal, raises GBP1 million
AN
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development
CI
RA International loss narrows as revenue grows
AN
ImmuPharma launches GBP2 million fund raise as interim loss narrows
AN
Earnings Flash (IMM.L) IMMUPHARMA Reports H1 Revenue GBP69,959
MT
Earnings Flash (IMM.L) IMMUPHARMA Posts H1 Loss GBX-0.25
MT
ImmuPharma plc Reports Earnings Results for the Half Year Ended June 30, 2023
CI
ImmuPharma Initiates Talks with Potential Partners for Licensing Deals
MT
Immunovia to Significantly Restructure to Focus Resources on Its Next-Generation Blood Test for Pancreatic Cancer Detection
CI
ImmuPharma plc Announces Further Positive Progress in Late-Stage Clinical Program in Patients with Chronic Idiopathic Demyelinating Polyneuropathy
CI
ImmuPharma annual loss narrows as R&D spending reduced
AN
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMM Stock
  4. News ImmuPharma plc
  5. Highlights